Ключевые слова:
экспериментальный атеросклероз, кролики, липидный спектр, Lp(a), антитела к Lp-PLA2, Биомайс, статин, комбинированная терапия.Библиографические ссылки
Асадуллаев М.М., Рахимбаева Г.С., Вахабова Н.М. Значение гендерных и возрастных факторов в патогенезе ишемического инсульта в современной медицине // Вестн. ТМА. – 2020. – №6. – С. 25-31.
Asadullaev M.M., Vakhabova N.M. Risk factors and background diseases in different pathogenetic subtypes of ischemic stroke // Int. J. Orange Technol. – 2020. – Vol. 2, №10. – Р. 86-88.
Asadullayev M.M., Vakhabova N.M. Epidemiology and structure of stroke in India: [subtitle if available] // Болезни кровообращения. – 2025. – №1 (3). – С. 93-98.
Cicero A.F.G., Colletti A. Nutraceuticals and Dietary Supplements in Lipid Management: Where Is the Evidence? // Curr. Opin. Lipidol. – 2020. – Vol. 31, №3. – P. 123-130.
Cicero A.F.G., Fogacci F., Stoian A.P. et al. Critical evaluation of the clinical evidence for nutraceuticals in the management of dyslipidemia // Exp. Opin Pharmacother. – 2022. – Vol. 23, №8. – P. 969-982.
Cicero A.F.G., Fogacci F., Stoian A.P., Toth P.P. Nutraceuticals in the Management of Dyslipidemia // Curr. Atherosc. Rep. – 2022. – Vol. 24, №12. – P. 963-975.
Grundy S.M., Stone N.J., Bailey A.L. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol // Circulation. – 2019. – Vol. 139 (25). – P. e1082-e1143.
Libby P., Buring J.E., Badimon L. et al. Atherosclerosis // Nat. Rev. Dis. Primers. – 2019. – Vol. 5, №1. – P. 56.
Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis // Nature. – 2011. – Vol. 473 (7347). – P. 317-325.
Mach F., Baigent C., Catapano A.L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias // Eurор. Heart J. – 2020. – Vol. 41, №1. – P. 111-188.
Nordestgaard B.G., Langsted A. Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology // J. Lipid. Res. – 2016. – Vol. 57, №11. – P. 1953-1975.
Packard C.J., O’Reilly D., Caslake M. et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease // N Engl. J. Med. – 2000. – Vol. 343, №16. – P. 1148-1155.
Roth G.A., Mensah G.A,. Johnson C.O. et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019 // J. Amer. Coll. Cardiol. – 2020. – Vol. 76 (25). – P. 2982-3021.
Sahebkar A., Katsiki N., Cicero A.F.G. Effects of plant sterols and stanols on lipid metabolism // Curr. Opin. Lipidol. – 2019. – Vol. 30, №3. – P. 199-206.
Thompson A., Gao P. et al. Lp-PLA2 Studies Collaboration, Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality // Lancet. – 2010. – Vol. 375 (9725). – P. 1536-1544.
Tousoulis D., Oikonomou E., Siasos G. et al. Dose-dependent effects of short-term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure // Atherosclerosis. – 2013. – Vol. 227, №2. – P. 367-372.
Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies // J. Amer. Coll. Cardiol. – 2017. – Vol. 69, №6. – P. 692-711.
Vakhabova N.M., Asadullaev M.M. Lipoproteins and their receptors association in ischemic stroke // J. Angiother. – 2024. – Vol. 8, №7. – Р. 1-6.